Caribou Biosciences just released new Phase 1 data for CB-011 in multiple myeloma showing a 92% overall response rate with manageable safety, via a company press release posted this morning. In small-cap biotech, fresh, clearly positive clinical data is among the highest-quality, tradable catalysts because (1) it reduces development risk, (2) expands the plausible addressable market narrative, and (3) often drives multi-day institutional and retail follow-through once the data are circulated across channels and digested by the street. The recency and source (company press release via GlobeNewswire) are strong. While early-phase results always carry caveats (sample size, durability, and confirmatory cohorts), a 90%+ response rate in relapsed/refractory myeloma is eye-catching and can support a repricing of expectations for this allogeneic CAR-T platform. Tactically, the setup is constructive. The last trade is 2.43 versus a prior close of 2.32, placing the stock above the 50-day EMA (~2.25) and roughly in line with its 9- and 21-day EMAs (~2.46 and ~2.44), with RSI near 51—balanced rather than overbought, allowing room for continuation. MACD histogram is modestly negative, reflecting a nascent pivot rather than a parabolic blow-off; for news-driven bios, that can improve quickly if volume expands post-print. There is a well-defined resistance band around the 52-week high near 3.00, which provides a clear tactical target. We propose an entry zone at 2.30–2.50 (close to EMA support and today’s quote), a stop at 2.10 (below recent swing support and 50-day EMA), and exits 2.80–3.00. That exit range offers roughly +12% to +24% from the midpoint of the entry zone, in line with the catalyst’s potential to drive a breakout retest. Position sizing and risk controls matter. Early-phase oncology is inherently volatile; if any follow-up disclosures or peer commentary temper enthusiasm (e.g., durability concerns, limited evaluable N), pullbacks can be swift. However, Caribou’s platform pedigree and the magnitude of the response rate shift the skew positive in the near term. The stock’s 52-week range (0.66–2.9995) shows it can move sharply; importantly, we’re not chasing at extremes—the print hit within the past few hours, and the technicals are mid-range. Catalyst longevity supports an 11-day horizon. Clinical headlines typically catalyze several trading sessions: day 1 press reaction, day 2–3 sell-side and KOL commentary, and days 4–10 broader momentum/short-covering if the story catches. Short-interest indicators in the supplied historical context show capacity for squeezes in prior periods; while we won’t overfit past data, positive data plus improving technicals can pull in shorts on the bid. Our confidence is bolstered by the clarity of the news (no ambiguity on directionality), the manageable safety framing, and alignment with a hot modality (off-the-shelf CAR-T). We do not assume approval from Phase 1 data; we simply trade the repricing window and target a retest of the prior 52-week high zone. The risk/reward is favorable with defined support (EMA50 ~2.25) and a tight stop just below, while upside to 2.80–3.00 is well within what similar small-cap oncology names have achieved on strong early data. Net-net: a clean clinical positive with room to run, justified 10%+ upside potential, and disciplined downside protection.